Please ensure Javascript is enabled for purposes of website accessibility
Home / Support / Research Spotlight

Alzheimer's disease: Pathogenesis, biomarkers, and emerging therapies
2026-07-17 42

Alzheimer's disease: Pathogenesis, biomarkers, and emerging therapies

Alzheimer's disease (AD) remains the leading cause of dementia worldwide and an escalating global health crisis. The hallmark amyloid plaques and neurofibrillary tangles (NFT) are now known to be accompanied by a complex array of pathologies that culminate in neurodegeneration and cognitive decline. New disease-modifying therapies for AD can now slow cognitive decline through the removal of amyloid plaques from the brain, but treatments to stop or prevent cognitive impairment remain elusive. In this review, we summarize the most recent updates in AD research on pathologic disease mechanisms and therapeutic strategies, highlighting advancements in apolipoprotein E (APOE) biology, neuroimmunology, biomarker discovery, and initial experience with new disease-modifying therapies. These important discoveries are revolutionizing AD diagnosis and treatment and provide hope for a future where AD is not only treatable but also preventable.
Keywords Alzheimer's disease amyloid-beta tau APOE neuroinflammation biomarkers disease-modifying therapies lecanemab donanemab TREM2

Research Tools from AntibodySystem

Amyloid & tau pathology Amyloid beta Tau APP BACE1
APOE & lipid metabolism APOE ABCA1 LDLR
Neuroinflammation & microglia TREM2 GFAP IBA1 CD68
Therapeutic targets Lecanemab Donanemab Gantenerumab
Adaptive immunity CD3 CD4 CD8 FOXP3
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only